Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company focused on rare diseases, is featured in a new Benzinga video detailing clinical pr ...

Watch here: Soligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding ...

Investing.com -- Shares of Soligenix (NASDAQ: SNGX) climbed 2.9% following the company’s announcement of promising results for its skin cancer treatment, HyBryteTM, in treating cutaneous T-cell ...

Prescient Therapeutics (ASX: PTX) has received fast-track designation from the US Food and Drug Administration for lead ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

Tumors develop when cells in the body grow uncontrollably ... However, tumors in dogs are most common in the skin, heart, and ...

SEATTLE, April 08, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...

Nearly one million people worldwide are plagued annually by cutaneous leishmaniasis, a devastating skin infection caused ... UMD Professor of Cell Biology and Molecular Genetics Najib El-Sayed ...

Brian Hess, director of CAR T cell therapy and lymphoma at Hollings. Those patients typically had a "very, very poor prognosis" where the chances of successful treatment were around 5 percent to ...

This innovative supplement harnesses the power of probiotics and prebiotics, promoting healthy skin cell turnover and aiding digestive health. By nurturing the beneficial bacteria in your gut ...

ALBANY, N.Y. — Dean Berhaupt has become the first patient to receive CAR T-cell therapy in Albany, marking a significant milestone for cancer treatment in the Capital Region. Berhaupt ...